The role of COX-2 in intestinal cancer

Christopher Williams, Rebecca L. Shattuck-Brandt, Raymond N. DuBois

    Research output: Contribution to journalArticlepeer-review

    88 Scopus citations

    Abstract

    Cyclooxygenase (COX), the key regulatory enzyme for prostaglandin synthesis is transcribed from two distinct genes. COX-1 is expressed constitutively in most tissues, and COX-2 is induced by a wide variety of stimuli and was initially identified as an immediate-early growth response gene. In addition, COX-2 expression is markedly increased in 85-90% of human colorectal adenocarcinomas, whereas COX-1 levels remain unchanged. Several epidemiological studies have reported a 40-50% reduction in the risk of developing colorectal cancer in persons who chronically take such nonsteroidal antiinflammatory drugs (NSAIDs) as aspirin, which are classic inhibitors of cyclooxygenase. Genetic evidence also supports a role for COX-2, since mice null for COX-2 have an 86% reduction in tumor multiplicity in a background containing a mutated APC allele. These results strongly suggest that COX-2 contributes to the development of intestinal tumors and that inhibition of COX is chemopreventative.

    Original languageEnglish (US)
    Pages (from-to)72-83
    Number of pages12
    JournalAnnals of the New York Academy of Sciences
    Volume889
    DOIs
    StatePublished - Jan 1 1999

    ASJC Scopus subject areas

    • Neuroscience(all)
    • Biochemistry, Genetics and Molecular Biology(all)
    • History and Philosophy of Science

    Fingerprint

    Dive into the research topics of 'The role of COX-2 in intestinal cancer'. Together they form a unique fingerprint.

    Cite this